Quarterly ResultMay 22, 2026, 04:07 PM
Abivax Obefazimod Study 108 Shows 68% UC Remission at Week 144; Q1 Cash €491.6M
AI Summary
Abivax reported its first quarter 2026 financial results and positive three-year interim data from Study 108, a Phase 2a/2b open-label extension trial of obefazimod in ulcerative colitis (UC) patients. The study showed strong durable clinical remission, with 68% of patients maintaining remission at week 144 after dose de-escalation, and no new safety signals observed over up to seven years of treatment. The company ended Q1 2026 with €491.6 million in cash, cash equivalents, and short-term investments, providing a cash runway into Q4 2027, and anticipates Phase 3 UC trial results in late Q2 2026.
Key Highlights
- Abivax's Study 108 showed 68% (88/130) UC patients in clinical remission at week 144.
- 80% (104/130) of patients completed 144 weeks of obefazimod treatment with no new safety signals.
- Cash, cash equivalents, and short-term investments totaled €491.6M as of March 31, 2026.
- Company projects cash runway into Q4 2027 based on current operating assumptions.
- Q1 2026 R&D expenses increased by €10.2M to €49.5M, driven by new indications.
- Q1 2026 net loss was €(48.5)M, an improvement from €(52.4)M in Q1 2025.
- Topline results for ABTECT Phase 3 UC maintenance trial expected in late Q2 2026.
- NDA submission for obefazimod in UC targeted for Q4 2026, pending positive data.
Price Impact
More from ABVX